AstraZeneca begins clinical trial of South African variant vaccine

The AstraZeneca Pharmaceutical announced this Sunday that it has begun a phase II / III clinical study to evaluate the safety and immune response generated by a new version of its coronavirus vaccine adapted to the beta variant, first identified in South Africa.

The British-Swedish multinational reported in a statement that today they received the first dose of this new vaccine, called AZD2816, the first participants in a study for which approximately 2,250 adults will be recruited in the United Kingdom, South Africa, Brazil and Poland.